In the light of the company’s continued progress, the Board of Directors of ADDvise Group have decided to raise the 2022 EBITDA target from the previous target communicated on 23 September 2021. For the financial year 2022, rolling 12 months pro forma basis, ADDvise expects to reach an EBITDA result of at least SEK 200 million before acquisition costs (adjusted EBITDA). The previous EBITDA target was at least SEK 150 million on a pro forma basis for 2022. The earlier communicated revenue target of SEK 1 billion in net sales on a pro forma basis before the end of 2022 remains unchanged.
ADDvise Group’s financial targets for 2022 are:
- 2022 EBITDA pro forma rolling 12 months target SEK 200 million
- 2022 net sales pro forma rolling 12 months target SEK 1 billion
“Our previous target of SEK 150 million in EBITDA will be reached pro forma in Q2. This, combined with the fact that we have good visibility of our acquisition pipeline means that we can increase our targets”. CEO Rikard Akhtarzand comments.
For further information, please contact:
CEO Rikard Akhtarzand
+46 765-25 90 71
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 7 April 2022 at 16:40 CEST.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.